cardiovascular agents

Product Profile: Sacuhart 50mg Sacuhart 50mg is a combination medication containing Sacubitril (a neprilysin inhibitor) and Valsartan (an angiotensin II receptor blocker). It belongs to the Angiotensin Receptor-Neprilysin Inhibitor (ARNI) class and is a landmark therapy for the management of chronic heart failure. 1. Clinical Indications & Usage Chronic Heart Failure: Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure (NYHA Class II-IV). Reduced Ejection Fraction: It is primarily utilized in patients with heart failure with reduced ejection fraction (HFrEF) to manage symptoms and improve survival outcomes. Mechanism of Coordination: Sacubitril: Inhibits the enzyme neprilysin, which prevents the degradation of natriuretic peptides. Increased levels of these peptides promote vasodilation, natriuresis, and myocardial relaxation. Valsartan: Blocks the AT1 receptors of angiotensin II, preventing vasoconstriction, sodium retention, and maladaptive cardiac remodeling. 2. Administration and Dosing Regimen: The medication is typically started at a low dose and titrated upward by a cardiologist to reach the target maintenance dose, based on patient tolerability and blood pressure response. Professional Requirement: Treatment initiation and dose adjustments must be performed under the supervision of a licensed cardiologist or physician specializing in heart failure. Consistency: Tablets should be taken consistently, regardless of food intake, to maintain steady-state serum levels. ⚠️ Safety, Side Effects, and Monitoring Contraindications: Contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy, concomitant use with ACE inhibitors (must observe a 36-hour washout period), and known hypersensitivity to any component of the drug. Critical Warnings: Hypotension: May cause symptomatic low blood pressure; blood pressure should be monitored during titration. Renal Function: Potential for impaired renal function, especially in patients with pre-existing renal artery stenosis. Hyperkalemia: Requires periodic monitoring of serum potassium levels. Angioedema: Patients must be educated to discontinue use and seek immediate emergency care if they experience swelling of the face, lips, tongue, or throat. Common Side Effects: Hypotension, hyperkalemia, dizziness, cough, and renal impairment. 📦 Storage, Stability & Commercial Packaging Storage: Store at controlled room temperature (20°C to 25°C / 68°F to 77°F). Protection: Keep in original blister packaging to protect from moisture and light. Security: Keep securely out of reach of children and unauthorized persons. PRESCRIPTION MEDICINE IS: YES. Disclaimer: This profile is compiled strictly for international wholesale procurement and commercial educational research. Sacuhart 50mg is a potent prescription medication and must be utilized strictly under the direct guidance of a licensed specialist. All import, distribution, and clinical usage must adhere strictly to the laws and pharmaceutical control regulations of the destination country. Failure to comply with local medical legislation regarding the usage of this product can result in severe legal consequences. 📞 Contact Ernest Impex — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Official Websites: www.ernestimpex.com www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com 📧 Corporate Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 📲 WhatsApp Link: https://wa.me/919359902383